Leading the Small Molecule Fight against RSV

Driving small molecule antiviral development for RSV (Respiratory Syncytial Virus) infection

Leading the Way: RV521
  • An RSV fusion (F) protein inhibitor
  • Best-in-class drug to treat RSV infections
  • Completed Phase 1 studies with antiviral exposures achieved
  • Completed RSV challenge model with high potency against both viral load and symptoms
  • Excellent safety profile
  • Entering an international multicentre Phase 2 paediatric trial

RSV: Serious Unmet Medical Need

  • RSV is a common and serious cause of respiratory infection in children, the immune-compromised and the elderly
  • It is the most important respiratory virus, responsible for one-fifth of all lower respiratory tract infections worldwide
  • RSV infection is responsible for more infant hospitalisations than other viral infections such as influenza
  • There are no effective treatments or vaccines available against RSV
  • It represents a significant unmet medical need
Meet the team...
Latest News
ReViral Announces Publication of Article in Journal of Medicinal Chemistry 'Perspectives'

ReViral today announced that the article “State of the Art in Respiratory Syncytial Virus Drug Discovery and Development”, written by ReViral’s Dr Stuart...

ReViral at 11th International Respiratory Syncytial Virus Symposium

ReViral's CEO, Dr Eddy Littler, and Head of Virology, Dr Elaine Thomas, will be presenting "Low rate of resistance to the RSV fusion inhibitor RV521 in human infection" at...

ReViral to present at RespiDART 2018

ReViral's Chief Scientific Officer, Stuart Cockerill, will be presenting at RespiDART 2018 in Miami on 29th November 2018. The afternoon session entitled "Therapeutics...

Contact us...